Cannabis and Glaucoma in Older Adults: What the Science Says

Core Data: Cannabinoids and Ocular Health

• THC Efficacy: May lower IOP by 15–25% for a duration of 3–4 hours.
• CBD Risk: Cannabidiol (CBD) has been shown to increase IOP in some studies, potentially counteracting the effects of standard glaucoma medications.
• Dosing Requirements: To maintain consistent IOP levels via cannabis, administration would theoretically be required 6–8 times per day.
• Metabolic Conflict: THC and CBD inhibit CYP450 enzymes, which may affect the metabolism of common blood thinners and antihypertensives.

Biological Mechanism of IOP Reduction

The human eye contains a concentration of CB1 receptors within the ciliary body and the trabecular meshwork—the tissues responsible for regulating aqueous humor production and drainage. THC acts as an agonist at the CB1 receptor, which may facilitate fluid outflow through the uveoscleral pathway while potentially curbing fluid production.

However, the aging process alters the sensitivity of the endocannabinoid system (ECS). Geriatric patients often exhibit reduced receptor density, which complicates the dose-response curve. The primary hurdle in clinical observation is the transient nature of the effect.

The CBD Counter-Indication

Research suggests that CBD may act as an antagonist to the pressure-lowering effects of THC. A study published in Investigative Ophthalmology & Visual Science demonstrated that CBD increased eye pressure in animal models by blocking CB1 receptors. For seniors using CBD products to manage chronic inflammation or sleep issues, this creates a potential risk: the product intended to provide relief may influence optic nerve health.

Pharmacokinetic Limitations of THC Monotherapy

Effective glaucoma management requires stable, 24-hour IOP control to support retinal ganglion cell health. THC-based protocols currently face challenges in meeting this standard.

1. The Short Half-Life Problem

The 3-to-4-hour therapeutic window provided by inhaled or sublingual THC is insufficient for nocturnal pressure control. Because IOP typically peaks in the early morning hours, maintaining a safe baseline would require frequent dosing throughout the night.

2. Delivery Method Risks

• Combustion/Vaping: These methods introduce carbon monoxide, which may reduce oxygen delivery to the optic nerve.
• Edibles: Longer duration (6–8 hours) comes at the cost of first-pass metabolism, leading to variable blood plasma levels and a potential for psychoactive impairment.
• Topicals: Current cannabis-infused eye drops often lack the bioavailability to penetrate the cornea effectively and are not a substitute for prescription ocular hypotensives.

Systemic Interactions and Polypharmacy

Seniors often manage multiple conditions via prescription medications. Introducing cannabinoids creates risks regarding Drug-Drug Interactions (DDIs).

Hepatic Metabolism (CYP450)

THC and CBD are processed by the CYP3A4 and CYP2C9 enzymes. These same pathways metabolize Warfarin, Statins, and Beta-blockers. Inhibiting these pathways can lead to altered levels of critical heart medications in the bloodstream.

Orthostatic Hypotension and Fall Risk

THC induces peripheral vasodilation, often resulting in a sudden drop in blood pressure when a patient stands. For a senior already dealing with compromised peripheral vision, this dizziness increases the statistical probability of bone fractures and head trauma.

Comparative Analysis: THC vs. Conventional Pharmaceuticals

Neuroprotection: The Secondary Research Frontier

Research is currently pivoting from simple IOP reduction to neuroprotection. There is evidence suggesting cannabinoids may offer antioxidant properties that support the optic nerve against oxidative stress, independent of eye pressure. While promising, this remains a speculative area of study and does not support the cessation of FDA-approved ocular hypotensives.

Clinical Protocol for Seniors

Patients considering the use of cannabinoids should follow a strict protocol to avoid the risk of vision loss:

1. Baseline Testing: Establish a current IOP baseline with an ophthalmologist before introducing THC.
2. Product Screening: Screen for CBD content to prevent unintended, rebound pressure spikes.
3. DDI Review: Conduct a full medication reconciliation with a pharmacist to identify potential CYP450 conflicts.
4. Monitored Introduction: Use low-dose sublingual tinctures to assess tolerance for orthostatic hypotension.
5. IOP Re-Check: Schedule a follow-up pressure check to determine if the cannabinoids are providing any measurable, sustained benefit.

Ultimately, cannabis is a systemic agent being applied to a localized, chronic condition. For the senior demographic, the systemic risks—including falls, complex drug interactions, and cognitive impairment—often outweigh the short-term benefits of IOP reduction. Conventional, clinically proven eye drops remain the gold standard for supporting the optic nerve and maintaining long-term vision.

---

Legal Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always seek the advice of a physician regarding a medical condition. Efficacy has not been confirmed by FDA-approved research. Check your local laws regarding cannabis and terpene use.

Sources

1. Hepler RS, Frank IR. (1971). Marihuana smoking and intraocular pressure. JAMA. 217(10):1392. PubMed

2. Tomida I, Pertwee RG, Azuara-Blanco A. (2004). Cannabinoids and glaucoma. Br J Ophthalmol. 88(5):708-13. PubMed

3. Miller S, Daily L, Leishman E, Bradshaw H, Straiker A. (2018). Δ9-Tetrahydrocannabinol and cannabidiol differentially regulate intraocular pressure. Invest Ophthalmol Vis Sci. 59(15):5904-5911. PubMed

4. Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. (1980). Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 87(3):222-8. PubMed